Key Highlights

  • GSK plc (LSE:GSK) is trending on 9 November 2026 as the FTSE 100 rose 1.02% to 10,782.87 and pharma stocks were compared with cyclicals.
  • Third-quarter turnover was £8.9 billion, up 5% and about 1% above forecasts, but a fall in Vaccine sales hit the shares on 28 October.
  • Analysts flagged that weakness in vaccines points to tougher trading in the coming quarters.
  • Investors are watching vaccine demand, HIV growth, the pipeline, Patent expiries and dividends.

Why GSK plc (LSE:GSK) Is in Focus Today

GSK plc (LSE:GSK) is trending on 9 November 2026 as investors reassess pharmaceutical stocks after a market rebound led by miners and airlines. The FTSE 100 closed 1.02% higher at 10,782.87, and defensive healthcare names lagged the cyclical rally, with Haleon and Smith & Nephew among the weaker performers. GSK remains in focus because of its third-quarter results on 28 October, when the shares fell after vaccine sales declined, even though group turnover beat forecasts.

AstraZeneca, the other large UK pharmaceutical stock, reported firm nine-month numbers on 30 October, which sets a contrast with GSK’s vaccine concerns.

Third-Quarter Results

GSK reported third-quarter turnover of £8.9 billion, up 5% on a year earlier and around 1% above analyst forecasts. The decline in vaccine sales, which include shingles and respiratory vaccines, overshadowed growth elsewhere. Chief market analysts said the vaccine weakness points toward tougher trading in coming quarters, which explains the share price reaction. Growth came from specialty medicines, including HIV, oncology and respiratory products.

Strategy and Pipeline

GSK is led by chief executive Luke Miels, who took over from Emma Walmsley in January 2026, and the company has outlined a goal of sustained growth in the 2030s through new vaccines and specialty medicines. The HIV franchise, led by long-acting injectables, remains a key profit driver, while pipeline Assets in oncology, respiratory and infectious disease are important to offsetting patent expiries on older products. Business development and bolt-on acquisitions have supplemented internal research.

Dividend and Capital Returns

GSK pays a quarterly Dividend and holds a high Yield compared with many large companies. The board balances dividend growth, pipeline Investment and acquisitions. For holders of LSE:GSK, cash generation and the ability to maintain growth after patent expiries are the key supports.

Risks Investors Are Weighing

Declining vaccine demand, pricing pressure in the United States, patent expiry on key HIV products later in the decade, litigation and clinical trial setbacks are the main risks. Policy changes on drug pricing and tariffs also matter, and the shares can fall sharply on a single weak sales line.

Specialty Medicines and Product Mix

GSK’s portfolio spans vaccines, specialty medicines and general medicines. Specialty medicines include HIV treatments from ViiV Healthcare, oncology products and respiratory drugs, and they account for the largest share of sales growth. Vaccines, including shingles and meningitis products, have been a significant earner but are exposed to changes in vaccination guidance and to competition. General medicines provide steady cash from established brands.

The mix explains the share price reaction in October: a decline in one high-margin vaccine line can outweigh growth elsewhere in the portfolio, because investors price in the Earnings that vaccines contribute. The company’s task is to show that new launches can offset such pressures over time.

Sector Context

AstraZeneca reported nine-month Revenue of $46.9 billion and core Earnings Per Share growth of 14% on 30 October, and its shares rose about 3% on the day, which highlights how divergent the UK pharma names can be. Investors therefore compare GSK’s pipeline and sales trends against AstraZeneca’s, and use each update to judge relative value. Policy on US drug pricing and tariffs affects both groups and drives sector-wide moves in LSE:GSK.

Closing Note

Investors also follow the timing of patent expiries for key HIV products and the progress of replacement long-acting treatments, since those events shape the earnings path beyond 2027.

Second Closing Note

Management commentary on 2027 guidance at the full-year results will be an important marker for dividend growth and for how the market values the vaccine franchise.

What Investors Are Watching Next

Investors will watch fourth-quarter vaccine demand, HIV growth, pipeline readouts and regulatory decisions, along with updates on US drug pricing policy. The full-year results will provide guidance for 2027 and the dividend outlook.

Valuation and Key Takeaways

GSK trades at a lower multiple than some pharma peers because of patent expiry concerns and vaccine volatility. The shares are likely to respond to pipeline news and quarterly trends, with the 28 October reaction showing how sensitive they are to vaccine sales. A more stable vaccine trend would help narrow the valuation gap.

Outlook

GSK plc (LSE:GSK) is a large FTSE 100 drugmaker with a deep pipeline but near-term pressure in vaccines. Today’s rotation toward cyclicals weighs on defensive names, while longer-term performance depends on new product launches.